Danaher Corporation Stock Price, News & Analysis

On April 25, 2023, Danaher Corporation (NYSE: DHR) disclosed its Q1 2023 financial results. The company reported net earnings of $1.4 billion or $1.94 per diluted share, alongside non-GAAP adjusted earnings of $2.36 per share. Total revenues fell 7.0% year-over-year to $7.2 billion, attributed to reduced COVID-19 revenue, while core revenue decreased by 4.0%. However, the base business core revenue grew 6.0%. The operating cash flow for the quarter stood at $1.9 billion, with free cash flow at $1.7 billion. For Q2 and the full year, non-GAAP base business core revenue growth is projected to be in the mid-single digits. CEO Rainer M. Blair noted a strong start despite challenges, highlighting a robust business outlook.

Danaher Corporation (NYSE: DHR) announced that its 5.00% Series B Mandatory Convertible Preferred Stock will convert automatically into common stock on April 17, 2023. Shareholders will receive 5.0175 shares of common stock for each share of Preferred Stock. Additionally, a final quarterly cash dividend of $12.50 per share will be distributed to Preferred Stock holders of record as of March 31, 2023, paid on the conversion date of April 17, 2023, due to the prior dividend date falling on a weekend.

This strategic move simplifies capital structure while rewarding investors with equity and dividend payments.

Danaher Corporation (NYSE: DHR) has scheduled its first quarter 2023 earnings conference call for April 25, 2023, at 8:00 a.m. ET. The call will focus on the company's financial performance and future expectations, lasting approximately one hour.

Listeners can access the call via telephone or through a webcast on Danaher's website. The earnings press release and presentation materials will also be available on the site starting at 6:00 a.m. ET on the day of the call.

Danaher Corporation (NYSE: DHR) has announced a strategic partnership with the University of Pennsylvania to enhance cell therapy innovation. This multi-year collaboration aims to develop technologies that improve clinical outcomes and address manufacturing bottlenecks associated with engineered cell products. Currently, there are six FDA-approved CAR T cell therapies and over 560 programs in clinical trials, highlighting significant potential in the biopharma industry. Both parties believe that advancing manufacturing innovation will help deliver next-generation therapies to patients more efficiently.

Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.27 per share for its common stock, set for payment on April 28, 2023, to stockholders of record by March 31, 2023. Additionally, a quarterly cash dividend of $12.50 per share for the 5.00% Series B Mandatory Convertible Preferred Stock will be paid on April 17, 2023, also to holders of record by March 31, 2023. Danaher focuses on solving complex challenges through its global science and technology initiatives, with a diverse workforce of about 81,000 employees.

Danaher Corporation (NYSE: DHR) announced the creation of a new public entity, Veralto Corporation, expected to launch in Q4 2023. Veralto will encompass Danaher’s Environmental and Applied Solutions (EAS) segment, which generated approximately $4.8 billion in revenue in 2022 and employs about 16,000 individuals. This standalone company will be led by Jennifer L. Honeycutt, Danaher's Executive VP. Veralto aims to list under the symbol VLTO on the New York Stock Exchange and will focus on improving global access to vital resources, including safe food and water. The name reflects the company's commitment to excellence.

Beckman Coulter Diagnostics and MeMed have announced a strategic partnership to enhance the Access Family of Immunoassay Analyzers by integrating the MeMed BV test. This diagnostic tool can differentiate between bacterial and viral infections, addressing overuse and underuse of antibiotics. The MeMed BV test has been validated in studies involving over 20,000 patients, gaining US FDA clearance and CE marking. Beckman Coulter aims to improve patient care and combat antimicrobial resistance through this innovation, with both companies optimistic about the potential healthcare outcomes from this collaboration.

Danaher Corporation (NYSE: DHR) announced its fourth quarter and full year 2022 results, showcasing significant growth. For Q4 2022, net earnings reached $2.2 billion ($2.99 per diluted share), marking a 25% increase year-over-year, while revenues increased by 2.5% to $8.4 billion. For the full year, net earnings totaled $7.1 billion ($9.66 per share), a 13.5% increase, with revenues up 7% to $31.5 billion. Non-GAAP metrics showed improved performance, with adjusted diluted net earnings growing by 6.5% in Q4 and 9% for the full year. The company forecasts mid-single digit growth for Q1 2023. CEO Rainer M. Blair highlighted strong execution and market share gains as key strengths.

Danaher Corporation (NYSE: DHR) announced that CEO Rainer M. Blair will present the fourth quarter 2022 financial performance at the J.P. Morgan Healthcare Conference on January 10, 2023. Estimated revenues are expected to rise in the low-single digits year-over-year, with non-GAAP core revenue growth projected in the high-single digits, exceeding previous guidance. Cepheid's molecular diagnostics business has notably contributed over $1 billion in respiratory testing revenues in the quarter. Danaher is optimistic about sustaining long-term shareholder value.